BridgeMD
New treatment option for Stroke
Official title Mindfulness With Dual-Task Training in Post-Stroke Mild Cognitive Impairment
ClinicalTrials.gov ID: NCT07603102
What this study is testing
- What it's testing
- This study aims to investigate whether a combined intervention of mindfulness and dual-task training can improve cognitive function and physical performance in individuals with mild cognitive impairment after stroke.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 55 and older
You may be able to join if
- Diagnosis of stroke confirmed by computed tomography (CT) or magnetic resonance imaging (MRI).
- Time since stroke onset ≥3 months and medically stable.
- Presence of mild cognitive impairment after stroke, defined by a Montreal - - Montreal Cognitive Assessment (MoCA) score \< 26.
- Mini-Mental State Examination (MMSE) score ≥ 24.
- Ability to walk independently with or without an assistive device for at least 10 meters.
You likely can't join if
- Severe aphasia, visual impairment, hearing impairment, or communication disorders that interfere with assessment or training participation.
- Severe depression or other major psychiatric disorders.
- Other neurological diseases affecting cognition or movement (e.g., Parkinson's disease, multiple sclerosis, traumatic brain injury).
- Severe musculoskeletal, cardiovascular, or systemic diseases that contraindicate exercise participation.
- Participation in other structured cognitive or rehabilitation intervention programs within the past 3 months.
- Unstable medical condition or recurrent stroke during the study period.
See the full eligibility criteria
- Diagnosis of stroke confirmed by computed tomography (CT) or magnetic resonance imaging (MRI).
- Time since stroke onset ≥3 months and medically stable.
- Presence of mild cognitive impairment after stroke, defined by a Montreal - - Montreal Cognitive Assessment (MoCA) score \< 26.
- Mini-Mental State Examination (MMSE) score ≥ 24.
- Ability to walk independently with or without an assistive device for at least 10 meters.
- Stable medication regimen for at least 4 weeks prior to enrollment.
- Ability to understand study instructions and provide written informed consent.
- Severe aphasia, visual impairment, hearing impairment, or communication disorders that interfere with assessment or training participation.
- Severe depression or other major psychiatric disorders.
- Other neurological diseases affecting cognition or movement (e.g., Parkinson's disease, multiple sclerosis, traumatic brain injury).
- Severe musculoskeletal, cardiovascular, or systemic diseases that contraindicate exercise participation.
- Participation in other structured cognitive or rehabilitation intervention programs within the past 3 months.
- Unstable medical condition or recurrent stroke during the study period.
- Inability to safely complete the training protocol as determined by the study investigators.
The study team makes the final eligibility decision.
Where it's taking place
- Nanjing, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 55 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nanjing, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.